UroGen Pharma Ltd.
Last updated September 27, 2026
Organization details
- Legal name
- UroGen Pharma Ltd.
- Ownership
- Public
- Status
- Active
- Headquarters country
- Israel
- Ticker symbol
- URGN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001668243
Board of directors
-
Arie Belldegrun · DirectorSince 2023
-
Cynthia M. Butitta · DirectorSince 2023
-
Daniel George Wildman · DirectorSince 2023
- Since 2023
-
James A. Robinson Jr. · DirectorSince 2023
-
Leana Wen · DirectorSince 2023
-
Ran Nussbaum · DirectorSince 2023
-
Stuart Holden · DirectorSince 2023
Board connections
6 of this board's directors also sit on 11 other boards.
- via Arie Belldegrun
- via Fred E. Cohen
- via Cynthia M. Butitta
- via James A. Robinson Jr.
- via Arie Belldegrun
- via Leana Wen
- via Fred E. Cohen
- via Ran Nussbaum
- via Fred E. Cohen
- via Cynthia M. Butitta
- via Fred E. Cohen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 9, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Option exercise | +1,666 | — | — |
| Sep 9, 2024 | Smith Jason Drew Officer (General Counsel) | Option exercise | +3,333 | — | — |
| Sep 9, 2024 | Kim Dong Officer (Chief Financial Officer) | Option exercise | +2,500 | — | — |
| Sep 9, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −859 | $13.08 | $11,236 |
| Sep 9, 2024 | Smith Jason Drew Officer (General Counsel) | Open-market sale | −1,521 | $13.08 | $19,895 |
| Jun 10, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Option exercise | +10,000 | — | — |
| Jun 10, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −5,153 | $13.08 | $67,401 |
| Mar 18, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −12,000 | $14.05 | $168,600 |
| Jan 31, 2024 | Smith Jason Drew Officer (General Counsel) | Option exercise | +834 | — | — |
| Jan 31, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Option exercise | +2,000 | — | — |
| Jan 31, 2024 | Kim Dong Officer (Chief Financial Officer) | Option exercise | +3,333 | — | — |
| Jan 31, 2024 | Smith Jason Drew Officer (General Counsel) | Open-market sale | −417 | $15.74 | $6,564 |
| Jan 31, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −1,137 | $15.74 | $17,896 |
| Jan 31, 2024 | Smith Jason Drew Officer (General Counsel) | Option exercise | +2,500 | — | — |
| Jan 31, 2024 | Schoenberg Mark Officer (Chief Medical Officer) | Option exercise | +1,333 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.